Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
June 8, 2026

EC grants marketing authorisation for IntraBio’s Aqneursa

The European Commission (EC) has granted marketing authorisation for IntraBio’s Aqneursa (levacetylleucine) to treat neurological symptoms of Niemann-Pick disease type C (NPC).

The approval is supported by data from a Phase III randomised, double-blind, placebo-controlled, crossover study in NPC patients. Credit: Mongkolchon Akesin / Shutterstock.com.